Intraventricular infusion of rt-PA in severe intraventricular haemorrhage after aneurysmal subarachnoid haemorrhage. A randomised clinical trial.

Submission date	Recruitment status	Prospectively registered
27/01/2006	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
27/01/2006	Completed	Results
Last Edited	Condition category	Individual participant data
14/08/2009	Circulatory System	[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr D. Nieuwkamp

Contact details

University Medical Center Utrecht Department of Neurology Heidelberglaan 100 Utrecht Netherlands 3584 CX d.nieuwkamp@neuro.azu.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

NTR455

Study information

Scientific Title

(Added 14/08/09) Recombinant tissue plasminogen activator (rt-PA) and external ventricular drain (EVD) in subarachnoid haemorrhage (SAH) with obstructive hydrocephalus for lysis of ventricular blood. A randomised clinical trial.

Acronym

RESOLVE

Study objectives

Intraventricular infusion of rt-PA reduces the frequency of poor outcome (death or dependency) in patients with a severe intraventricular haemorrhage after aneurysmal subarachnoid hemorrhage.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from local medical ethics committee

Study design

Single centre prospective randomised double blind placebo controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Aneurysmal subarachnoid haemorrhage, Hydrocephalus, Intraventricular haemorrhage

Interventions

- 1. Placement of external ventricular drain (standard procedure)
- 2. Clipping/Coiling of ruptured aneurysm (standard procedure)
- 3. Infusion of rt-PA or placebo through external ventricular drain

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Death or dependency 6 months after subarachnoid haemorrhage

Secondary outcome measures

- 1. Recurrent haemorrhage
- 2. Secondary ischaemia
- 3. Hydrocephalus
- 4. Bleeding complications from fibrinolysis
- 5. Death within 6 months
- 6. Rankin 0 versus Rankin 1-5 and death

Overall study start date

01/09/2005

Completion date

01/09/2009

Eligibility

Key inclusion criteria

- 1. First or recurrent aneurysmal subarachnoid haemorrhage with intraventricular extension of the haemorrhage
- 2. The ventricles must be enlarged and the intraventricular haemorrhage must be severe (Graebscore more than 6)
- 3. Patients must be in a poor neurological condition, WFNS <7 or WFNS <6 in intubated patients

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

16

Key exclusion criteria

- 1. Other cause for intraventricular haemorrhage than a subarachnoid haemorrhage from a ruptured intracranial aneurysm
- 2. Absence of both pupillary light reflexes
- 3. Use of oral anticoagulants
- 4. Treating physicians propose a palliative instead of curative treatment strategy
- 5. Absence of informed consent

Date of first enrolment

01/09/2005

Date of final enrolment

01/09/2009

Locations

Countries of recruitment

Netherlands

Study participating centre University Medical Center Utrecht

Utrecht Netherlands 3584 CX

Sponsor information

Organisation

University Medical Center Utrecht, Department of Neurology (The Netherlands)

Sponsor details

Heidelberglaan 100 Utrecht Netherlands 3584 CX

Sponsor type

Not defined

ROR

https://ror.org/0575yy874

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Medical Centre Utrecht (UMCU) (Netherlands)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration